AaiPharma Inc., of Wilmington, N.C., appointed David Hurley chief operating officer and Vijay Aggarwal president, research and development, with oversight of the development services organization.
ARYx Therapeutics Inc., of Santa Clara, Calif., elected Paul Goddard and Lars Ekman to its board, with Goddard as chairman.
Averion Inc., of Framingham, Mass., appointed Randy Bennett director of late phase studies and clinical monitoring.
BioVisioN AG, of Hannover, Germany, appointed Peter Schulz-Knappe chief scientific officer and a member of its executive board. Rainer Voegeli was added as chief business officer and head of business development and marketing. Hans-Dieter Zucht was named chief information officer.
CuraGen Corp., of New Haven, Conn., added Mary Taylor as vice president of regulatory affairs.
DiaDexus Inc., of South San Francisco, appointed John Keller to its board.
DOV Pharmaceutical Inc., of Hackensack, N.J., added Jonathan Silverstein to its board.
ILEX Oncology Inc., of San Antonio, promoted Steven Weitman to senior vice president and chief medical officer and Terry Murdock to senior vice president, clinical operations.
Illinois Biotechnology Industry Organization in Chicago elected Bill Gantz as its chairman for 2004 and elected Michael Flavin, Mich Hein and Donna Williamson to its board.
Interleukin Genetics Inc., of Waltham, Mass., added Jose Ordovas as a scientific advisor.
Isotechnika Inc., of Edmonton, Alberta, named David Kinniburgh vice president, laboratory operations.
LigoCyte Pharmaceuticals Inc., of Bozeman, Mont., added Charles Richardson as senior vice president, research and development.
NaPro BioTherapeutics Inc., of Boulder, Colo., appointed Anne Bailey vice president of diagnostics and reagents and general manager of its genomics division.
Nektar Therapeutics, of San Carlos, Calif., appointed Susan Wang to its board.
Pluristem Life Systems Inc., of Haifa, Israel, appointed Shmuel Levi chief financial officer.